Affimed PE Ratio 2014-2024 | AFMDQ
Current and historical p/e ratio for Affimed (AFMDQ) from 2014 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Affimed PE ratio as of May 22, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Affimed PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
|
0.00 |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
